ERBB2-eiwit (C-clavage, mens)

ERBB2

C-ERB-2, c-ERB2, CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, MLN19, NEU, NGL, p185 (erbB2), TKR1, VSCN2

C-cleavage

< 1.0 EU per μg protein as determined by the LAL method.

≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

1.Immobilized Human Her2/ERBB2 (Cat:10004-HCCH) at 2 μg/ml (100 μl/well) can bind Anti-HER2 (Research Grade Trastuzumab biosimilar), the EC50 is 7.0-30.0 ng/mL (QC tested) . 2. Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.3-1.5 μg/mL in the presence of 0.6 μg/mL Anti-ErbB2/Her2 Monoclonal Antibody (Routinely tested) . 3.Loaded Anti-HER2 (Research Grade Trastuzumab biosimilar) on ProA Biosensor, can bind Recombinant Human Her2 / ERBB2 Protein, no Tag (Cat. No. 10004-HCCH) with an affinity constant of 1.8 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested) . 4.Immobilized Recombinant Human HER2 / ErbB2 Protein (Cat: 10004-HCCH) at 1 μg/mL (100 μL/well) can bind Anti-HER2 (Research Grade Pertuzu*mab Biosimilar), the EC50 is 1.9 ng/mL (Routinely tested) .

Met1-Thr652

The recombinant human ERBB2 consists 636 amino acids and predicts a molecular mass of 70 kDa. As a result of glycosylation, human ErbB2 migrates as an approximately 100-110 kDa protein in SDS-PAGE under reducing conditions.

Human